Charles Schwab’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $36.4M | Sell |
2,514,240
-47,513
| -2% | -$681K | 0.01% | 1378 |
|
|
2025
Q4 | $36.5M | Sell |
2,561,753
-190,345
| -7% | -$1.87M | 0.01% | 1359 |
|
|
2025
Q3 | $21.7M | Buy |
2,752,098
+204,042
| +8% | +$1.45M | ﹤0.01% | 1687 |
|
|
2025
Q2 | $14.6M | Buy |
2,548,056
+56,976
| +2% | +$368K | ﹤0.01% | 1832 |
|
|
2025
Q1 | $20.3M | Sell |
2,491,080
-95,723
| -4% | -$886K | ﹤0.01% | 1636 |
|
|
2024
Q4 | $24.4M | Sell |
2,586,803
-80,468
| -3% | -$836K | ﹤0.01% | 1595 |
|
|
2024
Q3 | $28.5M | Buy |
2,667,271
+242,672
| +10% | +$2.64M | 0.01% | 1495 |
|
|
2024
Q2 | $24.1M | Buy |
2,424,599
+97,672
| +4% | +$1M | ﹤0.01% | 1556 |
|
|
2024
Q1 | $27.4M | Buy |
2,326,927
+58,041
| +3% | +$742K | 0.01% | 1431 |
|
|
2023
Q4 | $32.2M | Buy |
2,268,886
+90,195
| +4% | +$1.02M | 0.01% | 1292 |
|
|
2023
Q3 | $26.5M | Buy |
2,178,691
+72,674
| +3% | +$937K | 0.01% | 1311 |
|
|
2023
Q2 | $26.5M | Buy |
2,106,017
+39,859
| +2% | +$473K | 0.01% | 1292 |
|
|
2023
Q1 | $22.9M | Buy |
2,066,158
+975
| +0% | +$12K | 0.01% | 1366 |
|
|
2022
Q4 | $25.2M | Buy |
2,065,183
+44,518
| +2% | +$501K | 0.01% | 1271 |
|
|
2022
Q3 | $21.1M | Buy |
2,020,665
+32,529
| +2% | +$362K | 0.01% | 1338 |
|
|
2022
Q2 | $21.4M | Sell |
1,988,136
-16,598
| -0.8% | -$137K | 0.01% | 1361 |
|
|
2022
Q1 | $19M | Buy |
2,004,734
+47,117
| +2% | +$442K | 0.01% | 1591 |
|
|
2021
Q4 | $22.6M | Buy |
1,957,617
+86,684
| +5% | +$966K | 0.01% | 1488 |
|
|
2021
Q3 | $17.9M | Sell |
1,870,933
-207,571
| -10% | -$2.12M | 0.01% | 1672 |
|
|
2021
Q2 | $20M | Buy |
2,078,504
+57,977
| +3% | +$566K | 0.01% | 1587 |
|
|
2021
Q1 | $20M | Buy |
2,020,527
+122,560
| +6% | +$1.9M | 0.01% | 1531 |
|
|
2020
Q4 | $43.8M | Buy |
1,897,967
+4,578
| +0.2% | +$93.6K | 0.02% | 847 |
|
|
2020
Q3 | $26.7M | Sell |
1,893,389
-29,778
| -2% | -$434K | 0.01% | 1015 |
|
|
2020
Q2 | $29M | Buy |
1,923,167
+84,175
| +5% | +$1.03M | 0.01% | 923 |
|
|
2020
Q1 | $17M | Buy |
1,838,992
+188,216
| +11% | +$1.79M | 0.01% | 1122 |
|
|
2019
Q4 | $16.1M | Buy |
1,650,776
+107,210
| +7% | +$981K | 0.01% | 1363 |
|
|
2019
Q3 | $12.4M | Buy |
1,543,566
+100,139
| +7% | +$1.09M | 0.01% | 1474 |
|
|
2019
Q2 | $18M | Buy |
1,443,427
+251,854
| +21% | +$3.2M | 0.01% | 1215 |
|
|
2019
Q1 | $16.2M | Buy |
1,191,573
+150,212
| +14% | +$1.83M | 0.01% | 1241 |
|
|
2018
Q4 | $9.98M | Buy |
1,041,361
+6,456
| +0.6% | +$71K | 0.01% | 1460 |
|
|
2018
Q3 | $12.5M | Buy |
1,034,905
+45,899
| +5% | +$642K | 0.01% | 1484 |
|
|
2018
Q2 | $15.4M | Buy |
989,006
+77,388
| +8% | +$1.17M | 0.01% | 1275 |
|
|
2018
Q1 | $13.7M | Buy |
911,618
+147,843
| +19% | +$2.25M | 0.01% | 1268 |
|
|
2017
Q4 | $11M | Buy |
763,775
+31,900
| +4% | +$438K | 0.01% | 1407 |
|
|
2017
Q3 | $11M | Buy |
731,875
+138,941
| +23% | +$1.84M | 0.01% | 1350 |
|
|
2017
Q2 | $5.97M | Buy |
592,934
+29,983
| +5% | +$241K | 0.01% | 1701 |
|
|
2017
Q1 | $4.01M | Buy |
562,951
+30,177
| +6% | +$191K | ﹤0.01% | 1884 |
|
|
2016
Q4 | $2.65M | Buy |
532,774
+27,693
| +5% | +$192K | ﹤0.01% | 2052 |
|
|
2016
Q3 | $3.74M | Buy |
505,081
+45,280
| +10% | +$306K | ﹤0.01% | 1821 |
|
|
2016
Q2 | $2.51M | Buy |
459,801
+48,690
| +12% | +$341K | ﹤0.01% | 1953 |
|
|
2016
Q1 | $3.47M | Buy |
411,111
+43,415
| +12% | +$307K | ﹤0.01% | 1738 |
|
|
2015
Q4 | $3.57M | Buy |
367,696
+19,590
| +6% | +$177K | ﹤0.01% | 1736 |
|
|
2015
Q3 | $4.87M | Buy |
348,106
+195,402
| +128% | +$3.06M | 0.01% | 1492 |
|
|
2015
Q2 | $2.16M | Buy |
152,704
+138,904
| +1,007% | +$1.67M | ﹤0.01% | 2040 |
|
|
2015
Q1 | $151K | Hold |
13,800
| – | – | ﹤0.01% | 2994 |
|
|
2014
Q4 | $115K | Hold |
13,800
| – | – | ﹤0.01% | 3051 |
|
|
2014
Q3 | $83K | Hold |
13,800
| – | – | ﹤0.01% | 3045 |
|
|
2014
Q2 | $47K | Sell |
13,800
-41,400
| -75% | -$97.2K | ﹤0.01% | 3070 |
|
|
2014
Q1 | $115K | Hold |
55,200
| – | – | ﹤0.01% | 3026 |
|
|
2013
Q4 | $130K | Hold |
55,200
| – | – | ﹤0.01% | 3035 |
|
|
2013
Q3 | $131K | Hold |
55,200
| – | – | ﹤0.01% | 3014 |
|
|
2013
Q2 | $131K | Buy |
+55,200
| New | +$170K | ﹤0.01% | 3002 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Charles Schwab's FOLD Position: Q1 2026 in Review
Charles Schwab reduced its Amicus Therapeutics (FOLD) stake by 1.9% in Q1 2026, selling an estimated $681K and leaving 2,514,240 shares worth $36.4M. The position accounts for 0.01% of the portfolio, ranked #1378.
Charles Schwab first reported a position in FOLD in Q2 2013 and has held it in 52 quarters since. The position peaked at $43.8M in Q4 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Charles Schwab held 2,514,240 shares of Amicus Therapeutics worth $36.4M as of Q1 2026.
- Charles Schwab sold 47,513 Amicus Therapeutics shares in Q1 2026, an estimated $681K.
- Amicus Therapeutics made up 0.01% of Charles Schwab's portfolio in Q1 2026, its #1378 holding.
- Charles Schwab first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Charles Schwab's Amicus Therapeutics position peaked at $43.8M in Q4 2020.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.